The Kru¨ppel-like factor 5 (KLF5) is a zinc-finger transcription factor promoting cell proliferation, cellcycle progression and survival. A high expression level of KLF5 mRNA has been shown to be associated with shorter breast cancer patient survival. However, the mechanism of KLF5 action in breast cancer is still not clear. In this study, we found that both KLF5 and its downstream gene fibroblast growth factor binding protein 1 (FGF-BP) are co-expressed in breast cell lines and primary tumors. Manipulation of the KLF5 expression can positively regulate the FGF-BP mRNA and protein levels in multiple breast cell lines. In addition, the secreted FGF-BP protein in the conditional medium is also regulated by KLF5. Furthermore, we demonstrated that KLF5 binds and activates the FGF-BP promoter through a GC box by luciferase reporter, oligo pull down and chromatin immunoprecipitation (ChIP) assays. When FGF-BP is depleted by siRNA, KLF5 fails to promote cell proliferation in MCF10A, SW527 and TSU-Pr1. We further demonstrated that overexpression or addition of FGF-BP rescues the KLF5-knockdown-induced growth arrest in MCF10A cells. Finally, KLF5 significantly promotes MCF7 breast cancer cell xenograft growth in athymic nude mice. These findings suggest that KLF5 may promote breast cancer cell proliferation at least partially through directly activating the FGF-BP mRNA transcription. Understanding the mechanism of KLF5 action in breast cancer may result in useful diagnostic and therapeutic targets.
Introduction
Breast cancer is the second leading cause of cancer death in American women. Breast cancer initiation and development are usually regulated by transcription factors, such as p53, c-Myc and b-catenin. The Kru¨ppel-like factor 5 (KLF5, IKLF/BTEB2) transcription factor is ubiquitously expressed in multiple tissues and has been demonstrated to be a key regulator for development, angiogenesis, adipoctye differentiation and tumorigenesis (reviewed in McConnell et al., 2007) . KLF5 is highly expressed in immortalized breast epithelial cells but lost in many breast cancer cell lines (Chen et al., 2002) . However, the high expression level of KLF5 has been shown to be an unfavorable prognostic factor for disease-free survival and overall survival in patients with breast cancer (Tong et al., 2006) . In a most recent study (Ben-Porath et al., 2008) , KLF5 was reported to be one of the nine genes that are overexpressed in high-grade and poorly differentiated aggressive breast tumors. However, the involvement of KLF5 and the mechanism of KLF5 action in breast cancer are still not clear.
KLF5 has been well documented to promote cell proliferation, cell-cycle progression, migration and survival. Like other Sp/KLF transcription factors, KLF5 binds to GC-rich DNA sequences, such as the Sp1 site, GC box and CACCC box (Sogawa et al., 1993; Kojima et al., 1997; Zhang and Teng, 2003) through three zinc-finger domains. KLF5 has been shown to regulate transcription of a number of genes, such as the platelet-derived growth factor-a (PDGF-a) (Aizawa et al., 2004) , CyclinD1 (Bateman et al., 2004) , Pim1 (Zhao et al., 2008) and PPARg in different cell models. Two microarray studies revealed many KLF5-regulated genes in vitro and in vivo (Chen et al., 2006; Wan et al., 2008) . Among these KLF5-regulated genes, the fibroblast growth factor binding protein 1 (FGF-BP/HBP17) has been repeatedly identified (Chen et al., 2006; Wan et al., 2008) .
FGF-BP is a secreted protein that binds to FGFs in a noncovalent, reversible manner (Wu et al., 1991) . FGF-BP can release the immobilized FGFs (for example, bFGF) from the extracellular matrix and chaperone them to their receptors. FGF-BP has been suggested to be important in several physiological and pathological processes including epithelial development, wound healing and tumorigenesis (Kurtz et al., 1997 (Kurtz et al., , 2004 Aigner et al., 2001) . FGF-BP is lowly expressed in normal adult human tissues and upregulated in several tumor types including invasive breast cancer (Kagan et al., 2003) , prostate cancer, squamous cell carcinoma (Li and Chen, 2004) and colon cancer (Ray et al., 2003) . Inhibiting FGF-BP reduces tumor growth (Czubayko et al., 1994a; Tassi et al., 2006) . These findings suggest that FGF-BP is a potential therapeutic target for breast and other cancers. However, whether FGF-BP is a KLF5 direct target gene and mediates KLF5's function in breast cancer are unknown.
We hypothesized that FGF-BP is a KLF5 direct target gene in breast cancer. We further hypothesized that KLF5 promotes breast cell proliferation through FGF-BP. Here, we demonstrated that both KLF5 and FGF-BP are expressed in estrogen receptor (ER)-negative basal breast cancer cell lines. Immunohistochemistry (IHC) study in primary breast tumors confirmed the expression correlation of KLF5 and FGF-BP. Furthermore, KLF5 knockdown and overexpression control the FGF-BP mRNA and protein expression in multiple breast cancer cell lines. We identified an 11 bp GC-rich KLF5 binding site at the FGF-BP proximal promoter. Finally, we demonstrated that KLF5 promotes breast cell proliferation through FGF-BP. We thus provide evidence for the first time of the expression and functional coupling between KLF5 and FGF-BP in breast cancer. These findings provide important new insights into the role and action mechanism of KLF5 in breast cancer.
Results

KLF5 and FGF-BP proteins are co-expressed in breast cancer
In our previous studies (Chen et al., 2002 (Chen et al., , 2005b , KLF5 mRNA and protein have been demonstrated to be expressed in immortalized breast epithelial cell lines (for example, MCF10A) and several breast cancer cell lines (for example, SW527) but lost in many breast cancer cell lines (for example, MCF7). FGF-BP was identified as one of the KLF5 downstream target genes by two independent microarray studies (Chen et al., 2006; Wan et al., 2008) , we thus wondered if both KLF5 and FGF-BP proteins are co-expressed in breast cancer. Indeed, we found that both proteins are co-expressed in four ER-negative breast cell lines (MCF10A, SW527, BT20 and HCC1937) by immunoblotting ( Figure 1a ). In contrast, three ER-positive breast cancer cell lines, MCF7, BT474, and HCC1500, and an ER-negative breast cancer cell line, Hs578T, show little expression for both KLF5 and FGF-BP. This result suggests that the expression of the FGF-BP protein is highly correlated with the expression of the KLF5 protein in these breast epithelial cell lines.
To test if both KLF5 and FGF-BP are co-expressed in primary breast tumors, we stained KLF5 and FGF-BP in 36 breast carcinoma by IHC. Of the 36, 23 tumors examined showed a direct correlation between the expression of KLF5 and the expression of FGF-BP (P ¼ 0.03, Fisher's exact test; Table 1; Figure 1b) . These results further support that FGF-BP may be one of the KLF5 direct target genes in breast cancer. However, the correlations between KLF5/FGF-BP and ER/PR are not significant in these tumors probably because of the small size of tumor samples. Figure 2a ). We also examined the induction of EGFR, PDGF-a and CyclinD1 by KLF5 in MCF7, BT474 and Hs578T by qRT-PCR as they have been reported to be transcriptional targets of KLF5 in other cells (Aizawa et al., 2004; Bateman et al., 2004; Yang et al., 2006) . After KLF5 is overexpressed in these breast cancer cell lines by adenoviruses, the FGF-BP mRNA is dramatically upregulated whereas EGFR, PDGF-a and CyclinD1 mRNA levels are not significantly induced (Figure 2b ). These results suggest that FGF-BP could be a major KLF5 downstream target gene in breast cancer cell lines. To further test whether endogenous KLF5 also regulates the FGF-BP mRNA levels, we knocked down KLF5 by a well-characterized anti-KLF5 siRNA (Chen Both KLF5 and FGF-BP have been shown to be induced by phorbol ester (phorbol 12-myristate 13-acetate, TPA) (Harris et al., 1998; Sun et al., 2001) . If FGF-BP is a KLF5 target gene, it is possible that KLF5 is required for TPA to induce FGF-BP. To test this possibility, we first performed the dosage and time course experiments in Hs578T. Both KLF5 and FGF-BP mRNA levels are upregulated in Hs578T in doseand time-dependent manners ( Figure 2c ). Interestingly, the induction of KLF5 is obviously earlier than the induction of FGF-BP. These results suggest that KLF5 is an immediate TPA-responsive gene and the FGF-BP induction is secondary to the KLF5 induction, supporting the hypothesis that KLF5 may be responsible for FGF-BP mRNA's up-regulation by TPA in Hs578T. To test this possibility directly, we knocked down KLF5 by siRNA in Hs578T and measured the induction of FGF-BP mRNA, TPA fails to induce FGF-BP above levels in the Lucsi control ( Figure 2d ). Similar results were obtained in MCF7 by qRT-PCR ( Figure 2d ). These results clearly suggest that KLF5 is necessary for FGF-BP mRNA induction by TPA in Hs578T and MCF7.
KLF5 positively regulates the FGF-BP protein
To test whether endogenous KLF5 ultimately affects the FGF-BP protein expression, we knocked down KLF5 in three breast cell lines MCF10A, SW527 and BT20. An anti-FGF-BP siRNA was used as a positive control. We found that KLF5 depletion dramatically decreases the FGF-BP protein levels in these cell lines (Figure 3a ).
In addition, we found that KLF5 overexpression also upregulates the FGF-BP protein levels in TSU-Pr1, MCF7, HCC1500 and Hs578T ( Figure 3b ). K12 (KLF5 þ ) and V4 (KLF5À) are stable isogenic clones derived from TSU-Pr1 (Chen et al., 2006) . As expected, the FGF-BP protein level in K12 is much higher than that in V4. In MCF7 and HCC1500, transient KLF5 overexpression by adenovirus infection also increases the FGF-BP protein levels compared to GFP. Interestingly, we also detected a 17 kDa FGF-BP protein beside the typical 34 kDa FGF-BP protein in MCF7 . Finally, we demonstrate that KLF5 overexpression in Hs578T by lentivirus also increases the FGF-BP protein expression compared to LacZ.
FGF-BP is a secreted protein (Czubayko et al., 1997) . To test if the secreted FGF-BP in media is also regulated by KLF5, we collected and analysed the conditional media (CM) from the KLF5-depleted MCF10A and SW527 cells by western blot. As shown in Figure 3c , the secreted FGF-BP protein levels are significantly reduced by KLF5 siRNA compared to Luc siRNA in both cell lines. The FGF-BP siRNA also dramatically decreases the secreted FGF-BP protein levels in these cell lines.
KLF5 promotes the FGF-BP transcription through directly binding to a GC box at the FGF-BP promoter It is very likely that the KLF5 transcription factor regulates the FGF-BP mRNA transcription through the FGF-BP promoter. To test this, we manually analysed the FGF-BP proximal promoter (Harris et al., 1998 (Harris et al., , 2001 Kagan et al., 2003) and found two potential KLF5 binding sites (Figure 4a ). Then, we generated two luciferase reporter constructs by cloning the FGF-BP promoter (À217/ þ 61 and À128/ þ 61) into the PGL3-BASIC plasmid. The À217/ þ 61 construct contains two putative KLF5 binding sites whereas the À128/ þ 61 construct contains only one putative KLF5 binding site. By dual luciferase assays in MCF7, we found that both Figure 3 The Kru¨ppel-like factor 5 (KLF5) positively regulates the fibroblast growth factor binding protein 1 (FGF-BP) protein levels in breast cells. (a) KLF5 knockdown reduces the FGF-BP protein levels in three breast cell lines MCF10A, SW527 and BT20 as determined by western blot. Luc siRNA and FGF-BP siRNA were used as negative and positive controls. b-actin was used as a loading control. (b) KLF5 overexpression increases the FGF-BP protein levels in TSU-Pr1, MCF7, HCC1500 and Hs578T. V4 and K12 are KLF5 isogenic stable clones derived from TSU-Pr1 (Chen et al., 2006) . KLF5 was introduced into MCF7 and HCC1500 cells by adenovirus infection. The green fluorescent protein (GFP) adenovirus was used as a negative control. A 17 KDa FGF-BP protein was also increased in MCF7. KLF5 was stably expressed in Hs578T by lentiviruses. The cell populations were used. The LacZ gene was used as a negative control. (c) KLF5 knockdown decreases the secreted FGF-BP protein levels in the conditional media (CM) of MCF10A and SW527. CM was collected as described in Materials and methods.
constructs are significantly and similarly activated by KLF5 (Figure 4b, left) , suggesting that the second putative KLF5 binding site at the FGF-BP promoter is sufficient for KLF5-mediated transcription activation.
To further validate if the second putative KLF5 binding site is responsible for KLF5-mediated transcription activation, we mutated the binding site by substituting four Gs with A or T (Figure 4b , Figure 4 The Kru¨ppel-like factor 5 (KLF5) promotes the fibroblast growth factor binding protein 1 (FGF-BP) transcription through directly binding to a GC box at the FGF-BP proximal promoter. (a) The FGF-BP proximal promoter sequence (À217 to þ 61) contains two putative KLF5 binding sites as underlined. The transcription start site and other transcription factor binding sites are also indicated (Harris et al., 1998) . (b) KLF5 activates the FGF-BP promoter through a GC-rich box. Left: KLF5 equally activates both FGF-BP promoter constructs (À217/ þ 61 and À128/ þ 61), suggesting that the second putative KLF5 binding site is sufficient for KLF5-mediated transcription activation as determined by dual-luciferase assays in MCF7. Right: the mutation of the second KLF5 binding site (between À90 and À80) at the À128/ þ 61 construct abrogates basic promoter activity and KLF5-mediated transcription activation as determined by dual-luciferase assays in MCF7. Four Gs were mutated into A or T as indicated. The PGL3-BASIC was used as a negative control. The b-actin promoter driven renilla luciferase gene (pRL-b-actin) was used as the internal control. **Po0.01, t-test. (c) KLF5 binds to the wild-type (wt), but not mutant (mt), FGF-BP promoter in vitro as determined by oligo pulldown assays. The KLF5 protein was detected by western blot. The oligonucleotides from the mouse lactoferrin gene were used as a positive control. One hundred times more non-biotin-labeled wt or mt oligonucleotides were added as the KLF5 binding competitor. (d) KLF5 specifically binds to the FGF-BP promoter in vivo as determined by ChIP assays (primer sequences are shown in a). The input DNA and water were used as positive and negative controls for all PCRs. The anti-H3K4Me Ab was used as a positive control for ChIP because the tri-methylation at K4 of histone H3 is associated with active gene transcription (Santos-Rosa et al., 2002) . The negative control Ab (rabbit IgG) was the pre-bleed sera from the same rabbit used for generating the anti-KLF5 antibody. IgG also shows a faint background band because of nonspecific binding. The coding sequence (CDS) of FGF-BP was also amplified to test the binding specificity.
KLF5 promotes cell growth through FGF-BP
H-Q Zheng et al right). Indeed, the mutation completely abrogates the KLF5-mediated FGF-BP promoter activation in MCF7 cells, confirming that the second putative KLF5 binding site is necessary for FGF-BP promoter activation by KLF5. We then performed oligo pull-down assays in vitro to test if KLF5 directly binds to the FGF-BP promoter. In agreement with the luciferase results described above, the wild-type (wt), but not the mutant, biotinylated oligonucleotides from the FGF-BP promoter efficiently pull down the KLF5 protein overexpressed in MCF7 (Figure 4c, left) . Interestingly, the wt oligonucleotides from the FGF-BP promoter pull down even more KLF5 than the positive control oligonucleotides from the mouse lactoferrin gene (Shi et al., 1999) . These results were confirmed by a competition assay (Figure 4c , right). The specific binding between wt oligonucleotides from the FGF-BP promoter and the KLF5 protein is significantly abrogated in the presence of 100 times of non-biotinylated wt, but not mutant, oligonucleotides. These results suggest that KLF5 specifically binds to the second putative KLF5 binding site at the FGF-BP promoter in vitro.
Finally, we demonstrated that KLF5 binds to the FGF-BP promoter in vivo by chromatin immunoprecipitation (ChIP) assays in SW527. The anti-KLF5 antibody, but not the control rabbit IgG, specifically immunoprecipitates the promoter, but not the coding region, of the FGF-BP gene (Figure 4d ).
KLF5 promotes breast cell proliferation KLF5 has been shown to promote cell proliferation in multiple cell lines (Yang et al., 2005; Chen et al., 2006) . To test KLF5's role in breast cancer proliferation, we manipulated KLF5 protein levels in multiple breast cell lines and measured DNA synthesis. The DNA synthesis is significantly reduced in MCF10A and SW527 when KLF5 is knocked down by siRNA (Figure 5a) . We confirmed the results by measuring the growth of MCF10A and SW527 cells in the course of 5 days. The growth rates of KLF5 siRNA-transfected cells are slower than that of Luc siRNA-transfected cells (Figure 5b ). In addition, the DNA synthesis is significantly increased in MCF7 and BT474 when KLF5 is overexpressed by adenovirus infection (Figure 5c ).
To test whether KLF5 promotes breast cancer cell proliferation in vivo, we generated stable MCF7 populations overexpressing KLF5 and lacZ, respectively. The KLF5 and FGF-BP protein expression levels in these two populations are shown in Figure 5d . Consistent with the results in Figure 2b , stable KLF5 overexpression also upregulates FGF-BP like the transient KLF5 overexpression in MCF7. When the MCF7-lacZ and MCF7-KLF5 cells were injected into the mammary fat pads of the nude mice, MCF7-KLF5 cells grow significantly faster than MCF7-lacZ cells (Figure 5d ). The mean tumor weight from MCF7-KLF5 is about three times of that from MCF7-lacZ (Figure 5e ) after 40 days of growth in vivo.
KLF5 promotes breast cell proliferation through FGF-BP
To determine whether FGF-BP mediates KLF5's proproliferation function in breast cells, we first knocked down FGF-BP in MCF10A and SW527 and then measured the DNA synthesis. As expected, FGF-BP depletion alone, like KLF5 depletion, is sufficient to suppress the cell proliferation in both cell lines (Figure 6a) . Similar results were obtained by using another anti-FGF-BP siRNA (data not shown). Because the FGF-BP siRNA does not affect the KLF5 expression (Figure 3) , we deduced that KLF5, without FGF-BP, cannot promote cell proliferation. We further tested this hypothesis in TSU-Pr1 stable clones. As shown in our previous report (Chen et al., 2006) , the cell proliferation of K12 (KLF5 þ ) is faster than that of the V4 (KLF5À) clone. Both the KLF5 and FGF-BP protein levels are higher in K12 than in V4 ( Figure 6b ). As expected, KLF5 depletion completely reverses the FGF-BP expression and cell proliferation. Importantly, FGF-BP depletion also reverses the cell proliferation without reducing the KLF5 expression ( Figure 6b ). These results clearly suggest that KLF5 requires FGF-BP to enhance cell proliferation.
As shown earlier (Figures 2a, 3a , and 5a), KLF5 depletion significantly reduces the FGF-BP expression and suppresses cell proliferation in MCF10A. If KLF5 promotes cell proliferation through FGF-BP, addition of exogenous FGF-BP or overexpression of FGF-BP should be able to rescue the KLF5-depletion-induced growth arrest in MCF10A. We first used the FGF-BP protein expressed in the CM of HEK293T cells ( Figure 6c ). As predicted, the CM from FGF-BPtransfected HEK293T can significantly, although not completely, rescue the KLF5 siRNA-induced DNA synthesis decrease in MCF10A (Figure 6c ). To further test the hypothesis that KLF5 functions through FGF-BP, we overexpressed FGF-BP in MCF10A cells. Consistent with the previous results, the KLF5 siRNA decreases the DNA synthesis in MCF10A cells. However, in FGF-BP overexpressing MCF10A cells, the KLF5 siRNA cannot suppress the cell proliferation (Figure 6d ). These results further support our hypothesis that FGF-BP mediates KLF5's pro-proliferative function in breast cells.
Discussion
Compelling results suggest that KLF5 and FGF-BP occur in the same signaling pathways. First, both KLF5 and FGF-BP were reported to be induced by TPA (Harris et al., 1998; Sun et al., 2001; Sur et al., 2002) and the MAPK pathway (Harris et al., 2001; Sun et al., 2001; Chanchevalap et al., 2006) . In addition, microarray studies suggest that FGF-BP is a downstream gene of KLF5 in vitro and in vivo (Chen et al., 2006; Wan et al., 2008) . Functionally, both genes promote cell transformation and angiogenesis (Czubayko et al., 1997; Shindo et al., 2002) . Finally, both genes have been reported to be overexpressed in breast cancer (Kagan et al., 2003; Tong et al., 2006) . However, whether KLF5 directly binds to the FGF-BP promoter, upregulates its transcription and functions through FGF-BP in breast cancer are unknown.
In this study, we present evidence that FGF-BP is an important KLF5 direct target gene that partially mediates KLF5's pro-proliferation function in breast cancer. First, we demonstrated that both KLF5 and KLF5 promotes cell growth through FGF-BP H-Q Zheng et al FGF-BP are correlatively expressed in breast cell lines and primary tumors (Figure 1 ). Following that, we found that KLF5 tightly controls the FGF-BP mRNA and protein expression in multiple breast cell lines (Figures 2 and 3) . Importantly, KLF5 binds to the FGF-BP promoter in vitro and in vivo and activates the transcription of FGF-BP (Figure 4) . Finally, we showed that KLF5 functions through FGF-BP to promote cell proliferation (Figures 5 and 6 ). These results clearly suggest that KLF5 promotes cell proliferation, at least partially, through upregulating the FGF-BP transcription in breast cancer. FGF-BP has been shown to be regulated by several transcription factors, including C/EBPb (Kagan et al., 2003) and b-catenin (Ray et al., 2003) . Here we demonstrated that KLF5 is another critical transcription factor positively regulating FGF-BP transcription by directly binding to the GC box (Sp1 site) at the FGF-BP proximal promoter. Interestingly, KLF5 has been reported to interact with many other transcription factors including C/EBPb to regulate other target genes. It is possible that KLF5 and C/EBPb form a complex at the FGF-BP promoter and coordinately regulate the FGF-BP transcription.
KLF5 has been reported to be an independent prognosis marker in breast cancer because patients with higher KLF5 mRNA expression have shorter survival than patients with lower KLF5 expression (Tong et al., 2006) . This observation was further supported by independent microarray studies (Oncomine.org). Both KLF5 and FGF-BP mRNA levels are higher in ER/PRnegative than in ER/PR-positive tumors. Additional microarray analyses revealed that KLF5 levels are higher in basal-like invasive breast tumors than in non-basal-like tumors. Consistently, FGF-BP mRNA is also overexpressed in invasive breast tumors (Kagan et al., 2003) . Here we demonstrated that both KLF5 and FGF-BP proteins are mostly expressed in ER-negative, basal-like and invasive breast cancer cell lines and primary breast tumors (Figure 1 ). These findings imply that both KLF5 and FGF-BP may serve as potential molecular biomarkers for invasive breast cancer. We did not observe the negative correlation between KLF5/ FGF-BP and ER/PR in primary breast tumors possibly due to a small case number (36 tumors). It would be interesting to investigate the protein expression of KLF5/FGF-BP and ER/PR in a larger number of clinical breast tumors by IHC in the future.
Whether KLF5 is an oncogene or tumor suppressor gene in vivo is still debatable (Sur et al., 2006; Kwak et al., 2008) . In breast cancer, we originally proposed KLF5 as a putative tumor suppressor largely because the KLF5 expression is high in immortalized breast cell lines but is low in the majority of breast cancer cell lines (Chen et al., 2002) . However, we found that KLF5 actually promotes cell cycle and tumorigenesis in the TSU-Pr1 bladder cancer cell line (Chen et al., 2006) . In this study, we performed extensive DNA synthesis and growth assays by knocking down the endogenous KLF5 and overexpressing KLF5 in multiple cell lines and found that KLF5 promotes breast cell proliferation in vitro. Following that, we demonstrate that KLF5 promotes breast tumorigenesis in vivo by using the MCF7 breast cancer cell line (Figures 5d and e) . As a KLF5 direct target gene, FGF-BP has been well documented to promote cell proliferation, migration, anchorage-independent growth, angiogenesis and tumorigenesis (Czubayko et al., 1994a (Czubayko et al., , b, 1997 Aigner et al., 2001; Ray et al., 2006; Tassi et al., 2006) . These results suggest that KLF5 may actually promote breast cancer progression. If so, the Am80 small molecular inhibitor of KLF5 and anti-FGF-BP monoclonal antibody may be used for invasive breast cancer treatment. However, the exact function of KLF5 in breast cancer development needs to be tested in vivo by using KLF5 conditional knockout and breast-specific transgenic mouse models.
KLF5 has been shown to promote cell proliferation through regulating several target genes such as CyclinD1 (Bateman et al., 2004) , PDGF-a (Aizawa et al., 2004) and EGFR (Yang et al., 2006) . However, we found that the expression of these genes is not induced as FGF-BP by KLF5 in MCF7, BT474 and Hs578T (Figure 2b ), suggesting that their regulation by KLF5 is context dependent. In contrast, the upregulation of FGF-BP by KLF5 appears not to be limited in breast cancer. In the TSU-Pr1 bladder cancer cell line (Figures 2b and 6b ) and the mouse lung (Chen et al., 2006; Wan et al., 2008) , FGF-BP is also positively regulated by KLF5. Several lines of evidence presented in Figure 6 strongly suggest that KLF5 promotes DNA synthesis partially through FGF-BP. FGF-BP was proposed to bind to and release FGFs from the extracellular matrix and to promote tumor cell growth and angiogenesis (Abuharbeid et al., 2006) . The action mechanism of FGF-BP in breast cancer requires further investigation.
In summary, we demonstrated that both KLF5 and FGF-BP are co-expressed in breast cancer cell lines and primary breast tumors. The KLF5 transcription factor tightly controls the FGF-BP gene transcription through binding to the GC-rich/Sp1 site at the FGF-BP promoter. Functionally, FGF-BP partially mediates the pro-proliferation function of KLF5 in breast cells. We demonstrated that KLF5 promotes breast tumorigenesis in vivo. These findings may provide rationale for developing KLF5 and FGF-BP for breast cancer diagnosis and therapy.
Materials and methods
Tissue culture and transfection MCF10A, MCF7 and HEK293T cell lines were cultured as described (Chen et al., 2007b) . SW527, BT-20 and BT474 
Antibodies and western blot
The western blot and anti-KLF5 antibody have been described in our previous study (Chen et al., 2005b) . The anti-FGF-BP antibody was purchased from R&D Systems (Minneapolis, MN, USA; AF1593) and diluted 500 times for western blot. The secondary antibody was usually diluted 10 000 times for all primary antibodies except for FGF-BP (5000 Â ). Super-signal west Femto Luminal/Enhancer Solution (Thermo Fisher Scientific Inc.) was used for imaging.
RT-PCR and quantitative RT-PCR
Semiquantitative PCR was used to measure the mRNA expression of KLF5 and FGF-BP. For quantitative RT-PCR, we used the ABsolute SYBR Green Fluorescein system (Thermo Fisher Scientific Inc.). The primer sequences for KLF5, FGF-BP, EGFR and CyclinD1 will be provided on request. Primers for GAPDH (Chen et al., 2007a) and PDGF-a (Chen et al., 2005a) have been published in our previous studies.
Conditional media
The full-length FGF-BP cDNA was amplified by RT-PCR. The PCR products were cloned into the pLenti6 vector (Invitrogen). The inserts were confirmed by DNA sequencing. SW527, MCF10A and HEK293T cells were seeded in six-well plates and transfected with either siRNA or plasmids the next day. Two days after transfection, the cells were replaced with 2 ml fresh serum-free medium and incubated for 24 h. The media were then collected and centrifuged at 900 g to remove any cell debris. The CM were then loaded into an Amicon 30 kDa filter centrifuge (UFC803024; Millipore, Billerica, MA, USA) and centrifuged at 900 g for 45 min. The concentrated media in the upper tube were used for western blot and thymidine incorporation assays.
Dual luciferase assay
The FGF-BP proximal promoters were amplified using normal human DNA as templates. The PCR products were cloned into the pGL3-BASIC (Promega, Madison, WI, USA). The inserts were confirmed by DNA sequencing. MCF7 cells were seeded in 24-well plates at 1 Â 10 5 cells per well. The next day, the cells were transfected with the FGF-BP promoter reporter constructs (0.6 mg per well) and an internal control pRL-bactin (5 ng per well) in triplicate. At 24 h after transfection, the cells were infected with a GFP control adenovirus and a KLF5 adenovirus (Chen et al., 2006) , respectively, for 4 h (B50% cells were infected under a fluorescence microscope). At 24 h after infection, luciferase activities were measured by using the dual luciferase reporter assay system (Promega).
Oligo pull-down assay KLF5 adenovirus-infected MCF7 cells in a 150-mm dish were lysed in 3.5 ml HKMG buffer (100 mM KCl, 10 mM HEPES (pH 7.9), 10% glycerol, 1 mM DTT, 5 mM MgCl 2 , 0.5% Igepal CA-630, 1% protease inhibitor cocktail). The cells were then sonicated. The supernatant was preincubated with 25 ml streptavidin-agarose for 1 h at 4 1C. The biotinylated doublestranded oligonucleotides (0.5 mg) were incubated with 1 ml 5 Â diluted precleared cell lysate in the presence of 10 mg of poly(dI-dC):poly(dI-dC) overnight at 4 1C. Following that, 25 ml streptavidin-agarose beads were added for 1 h at 4 1C. The beads were collected by centrifuging and washed with the HKMG buffer three times. The protein was eluted by adding 20 ml 3Â SDS-polyacrylamide gel electrophoresis loading buffer. The KLF5 protein was detected by western blot. For competition assays, 100 Â excess non-biotinylated oligonucleotides were used. The wild-type (wt) oligonucleotide sequence is 5 0 -CGGCTCCCTCGGAGGGGCGTGGCTGG GAGG-3 0 . The mutant oligonucleotide sequence is 5 0 -CGG CTCCCTCGAAGAGACTTGGCTGGGAGG-3
0 . An oligo (5 0 -GATCGGGCAATAGGGTGGGGCCAGCCC-3 0 ) binding to KLF5 was used as a positive control (Shi et al., 1999) .
Chromatin immunoprecipitation assay
The ChIP assay was performed using the SW527 cells following a protocol provided by Abcam (Cambridge, MA, USA). The diluted DNA-protein complex (25 mg protein) was incubated with different antibodies (anti-KLF5 Ab, rabbit IgG and anti-H3K4Me Ab (histone H3 (tri methyl K4)) antibodies; Abcam) overnight at 4 1C in the presence of herring sperm DNA and protein A/G beads. PCR was performed by using primers for the FGF-BP promoter to amplify the À217 to þ 61 region: (5 0 -GTTGTCCTCCTATCCTGGCC-3 0 (forward) and 5 0 -GGAGTGAATTGCAGGCTGC-3 0 (backward)). For the FGF-BP coding sequence 385-771, two primers (5 0 -TGCTGG CAATCCAACCTC-3 0 (forward) and 5 0 -GTCCTGCAC TATGCTGAGGA-3 0 (backward)) were used.
Thymidine incorporation assay
Cells were treated as necessary and incubated in media with 2 mCi/ml 3 H-thymidine (MP Biomedical, Solon, OH, USA) overnight. The cells were washed with the phosphate-buffered saline and fixed with 10% trichloroacetic acid. After washing, DNA was then dissolved with 120 ml 0.3 M NaOH and transferred to glass fiber filters. The incorporated 3 H-thymidine was measured by the Beckman LS-6500 scintillation counter after adding 5 ml Scienti-safe cocktail solution (Thermo Fisher Scientific Inc.).
IHC staining
The anti-KLF5 (1:400 dilution) and anti-FGF-BP (1:500 dilution) antibodies were used for IHC after validation and optimization. Two continuous breast carcinoma tissue microarray slides were purchased from US Biomax (Rockville, MD, USA, catalog no. BR961). The ER/PR/HER2 statuses for 36 primary breast tumors are available online (http://www.biomax.us/tissue-arrays/Breast/BR961). Antigens were retrieved either by 5 Â citrate buffer (0.05 M citric acid (pH 6.0), microwave for KLF5) or by 0.1 M Tris-HCl (pH 9.0) solution (boiling for FGF-BP). A standard DAB staining protocol was used. Immunostained slides were scored using the 'Allred score' method (Mohsin et al., 2004) .
Tumorigenesis in nude mice
The KLF5 cDNA was subcloned into pLenti6/V5-DEST vector. Stable MCF7 cell populations overexpressing KLF5 and lacZ were prepared by lentivirus transduction and blasticidin selection. The expression of KLF5 and FGF-BP was confirmed by immunoblotting. Twelve female athymic nude mice (4-to 5-week old; Harlan, Indianapolis, IN, USA) were used for this study (6 mice for each group). Each nude mice was implanted with a 0.18 mg 17b-estradiol pellet (90 days release; Innovative Research of America, Sarasota, FI, USA) to support the growth of MCF7. One day after the implantation, five million cells per site (two sites for each mouse) were injected into mammary fat pads of nude mice. The tumor volume was measured twice a week from day 12. The tumor volume is calculated as ½ Â (length) Â (width) 2 . All mice were killed at day 40 and the final tumor weights were recorded.
Retrovirus construction pBabe-puro-FGF-BP was constructed by inserting the FGF-BP gene into the pBabe-puro retroviral vector. The MCF10A cell populations expressing FGF-BP or the empty vector were generated according to a published protocol (Wang and Zhao, 2007) .
Statistical analysis
The luciferase assays and the DNA synthesis assays were conducted in triplicate. When appropriate, the data were pooled to generate means ± standard deviation and were analysed by t-test. Fisher's exact test was used to examine the expression correlation between KLF5 and FGF-BP in primary tumors. P-values of less than 0.05 were considered to be significant.
